In patients with hormone-receptor (HR)-positive metastatic breast cancer and low or ultra-low levels of HER2 expression, Enhertu led to a...

A patient who received TSHA-102 had durable improvements in motor skills, communication, and socialization. TSHA-102 was well tolerated with no...

ANX005 led to significant reductions in GBS-associated disability, improved muscle power, reduced nerve damage, and a reduced need for mechanical...

1. Onyda XR is the only non-stimulant medication with nighttime dosing indications. 2. Onyda XR can be added as an...

Awiqli led to greater glycated hemoglobin (HbA1c) reduction, superior blood sugar reduction, and time spent within the recommended blood sugar...

ENV-101 is a safe and well-tolerated, unique, disease-modifying agent in the treatment of IPF. ENV-101 not only improved lung function...

DB-OTO gene therapy has been shown to improve auditory response in children with congenital hearing loss DB-OTO is a promising...

Leqembi reduced amyloid markers in early Alzheimer's disease and resulted in moderately less decline in measures of cognition and function...

Elinzanetant reduced the frequency and severity of menopause-associated vasomotor symptoms in two phase 3 clinical trials. Elinzanetant was safe and...

Patients who received CT-388 had an average placebo-adjusted weight loss of 18.8%. CT-388 is well tolerated with only mild to...